Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein

Cancer Gene Therapy

Volumn 17, Issue 12, 2010, Pages 844-854

  Shao, Y ^a   Liu, Y ^a   Shao, C ^a   Hu, J ^b   Li, X ^a   Li, F ^a   Zhang, L ^a   Zhao, D ^a   Sun, L ^a   Zhao, X ^a   Kopecko, D J ^c   Kalvakolanu, D V ^d   Li, Y ^a   Xu, D Q ^c  

^a Basic Medical College   (China)

^b UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

p53; prostate cancer; siRNA; survivin

Indexed keywords

CYCLIN DEPENDENT KINASE 4; MYC PROTEIN; PROTEIN P53; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

MUS MUSCULUS;

EID: 78349313243     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.41     Document Type: Article

References (46)

1. Cancer Facts & Figures 2008. 2009. Available from http://www.cancer.org.
2. Woraratanadharm J, Rubinchik S, Yu H, Dong JY. Novel system uses probasin-based promoter, transcriptional silencers and amplification loop to induce high-level prostate expression. BMC Biotechnol 2007; 7: 9.
3. Vinall RL, Tepper CG, Shi XB, Xu LA, Gandour-Edwards R, de Vere White RW. The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene 2006; 25: 2082-2093.
4. Yu Q. Restoring p53-mediated apoptosis in cancer cells: New opportunities for cancer therapy. Drug Resist Updat 2006; 9: 19-25.
5. Liu S, Seidel-Dugan C. In search of p53 target genes for the therapeutic manipulation of cancer. Curr Opin Drug Discov Devel 2006; 9: 176-183.
6. Croci DO, Cogno IS, Vittar NB, Salvatierra E, Trajtenberg F, Podhajcer OL et al. Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem 2008; 105: 381-390.
7. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD et al. Prognostic importance of survivin in breast cancer. Br J Cancer 2003; 88: 1077-1083.
8. Esteve PO, Chin HG, Pradhan S. Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem 2007; 282: 2615-2625.
9. Wang YB, Liu YL, Wang P, Fu XL, Sun ZX. RNA interference inhibits the expression of survivin and induces the apoptosis of PC-3 cells. Zhonghua Nan Ke Xue 2007; 13: 983-987.
10. Zaffaroni N, Pennati M, Folini M. Validation of telomerase and survivin as anticancer herapeutic targets using ribozymes and small-interfering RNAs. Methods Mol Biol 2007; 361: 239-263.
11. Iwasaka T, Zheng PS, Ouchida M, Yamasaki H, Yokoyama M, Sugimori H. Cytologic changes in two cervical carcinoma cell lines after transfection of the wild-type p53 gene. Acta Obstet Gynecol Scand 1996; 75: 797-803.
12. Hamada K, Alemany R, Zhang WW, Hittelman WN, Lotan R, Roth JA et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996; 56: 3047-3054.
13. Jackson P, Ow K, Yardley G, Delprado W, Quinn DI, Yang JL et al. Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpression. Prostate Cancer Prostatic Dis 2003; 6: 174-181.
14. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-539.
15. Reihsaus E, Kohler M, Kraiss S, Oren M, Montenarh M. Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. Oncogene 1990; 5: 137-145.
16. Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D et al. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 2005; 11: 6333-6341.
17. Hu J, Angell JE, Zhang J, Ma X, Seo T, Raha A et al. Characterization of monoclonal antibodies against GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. J Interferon Cytokine Res 2002; 22: 1017-1026.
18. Albrecht S, Connelly JH, Bruner JM. Distribution of p53 protein expression in gliosarcomas: an immunohistochemical study. Acta Neuropathol 1993; 85: 222-226.
19. Zhang L, Gao L, Li Y, Lin G, Shao Y, Ji K et al. Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth. Clin Cancer Res 2008; 14: 559-568.
20. Chidambaram NV, Angell JE, Ling W, Hofmann ER, Kalvakolanu DV. Chromosomal localization of human GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. J Interferon Cytokine Res 2000; 20: 661-665.
21. Griewe GL, Dean RC, Zhang W, Young D, Sesterhenn IA, Shanmugam N et al. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. Prostate Cancer Prostatic Dis 2003; 6: 281-285.
22. Fangusaro JR, Caldas H, Jiang Y, Altura RA. Survivin: an inhibitor of apoptosis in pediatric cancer. Pediatr Blood Cancer 2006; 47: 4-13.
23. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021.
24. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53: 3369-3373.
25. Tsuji N, Furuse K, Asanuma K, Furuya M, Kondoh K, Kamagata C et al. Mutations of the p53 gene and loss of heterozygosity at chromosome 17p13.1are associated with increased survivin expression in breast cancer. Breast Cancer Res Treat 2004; 87: 23-31.
26. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808-1812.
27. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002; 86: 886-892.
28. Das A, Tan WL, Teo J, Smith DR. Expression of survivin in primary glioblastomas. J Cancer Res Clin Oncol 2002; 128: 302-306.
29. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-134.
30. Mehta R, Kyshtoobayeva A, Kurosaki T, Small EJ, Kim H, Stroup R et al. Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res 2001; 7: 81-88.
31. Guan M, Chen Y. Aberrant expression of DDNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol 2005; 58: 1175-1179.
32. Gomase VS, Tagore S. RNAi\a tool for target finding in new drug development. Curr Drug Metab 2008; 9: 241-244.
33. Størvold GL, Andersen TI, Perou CM, Frengen E. siRNA: a potential tool for future breast cancer therapy? Crit Rev Oncog 2006; 12: 127-150.
34. McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM. Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 2002; 51: 133-140.
35. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-3257.
36. Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M et al. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to driamycin. Int J Cancer 2006; 118: 812-820.
37. Miao GY, Lu QM, Zhang XL. Downregulation of survivin by RNAi inhibits growth of human gastric carcinoma cells. World J Gastroenterol 2007; 13: 1170-1174.
38. Liu WS, Yan HJ, Qin RY, Tian R, Wang M, Jiang JX et al. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci 2009; 54: 89-96.
39. Bolton MA, Lan W, Powers SE, McCleland ML, Kuang J, Stukenberg PT. Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell 2002; 13: 3064-3077.
40. Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 2003; 14: 3325-3341.
41. Wheatley SP, Carvalho A, Vagnarelli P, Earnshaw WC. INCENP is required for proper targeting of survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol 2001; 11: 886-890.
42. Colnaghi R, Connell CM, Barrett RM, Wheatley SP. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006; 281: 33450-33456.
43. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007; 28: 1133-1139.
44. Ho JS, Ma W, Mao DY, Benchimol S. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 2005; 25: 7423-7431.
45. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2: 764-776.
46. Hellsten R, Johansson M, Dahlman A, Dizeyi N, Sterner O, Bjartell A. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Prostate 2008; 68: 269-280.